Key result
High BAN-ADHF score linked to ~280% higher 5-year mortality in acute HFpEF.
Why the study?
Reliable prognostic tools for acute HFpEF remain limited, and the value of the BAN-ADHF score for long-term prognosis has not been explored.
Does the BAN-ADHF score predict 5-year all-cause mortality in patients admitted with acute HFpEF?
Cohort (n=143)
Does the BAN-ADHF score predict 5-year all-cause mortality in patients admitted with acute HFpEF?
The BAN-ADHF score serves as an independent predictor of 5-year all-cause mortality in patients hospitalized with acute HFpEF, extending its utility beyond short-term prognosis.
Elevated BAN-ADHF score flags higher long-term mortality in acute HF; leaves open incremental value for risk stratification.
Introduction Acute heart failure with preserved ejection fraction (HFpEF) constitutes a growing proportion of heart failure hospitalizations, yet reliable prognostic tools for this complex phenotype remain limited. The recently developed BAN-ADHF score, derived from routine clinical and laboratory data, has been validated as a short-term predictor in acute heart failure setting, but its value for long-term prognosis has not been explored. (1,2) This study aimed to assess the prognostic value of the BAN-ADHF score for 5-year all-cause mortality in patients admitted with acute HFpEF. Methods and Results A total of 143 consecutive patients (64% female, mean age 73.9 years) hospitalized for acute HFpEF were analyzed. Follow-up period was 5 years and data were available for 111 patients. According to the BAN-ADHF classification, patients were categorized as low-risk (<12 BAN-ADHF score) and high-risk (≥12 BAN-ADHF score). A total of 58 patients (52.3%) died during follow-up. Mortality was markedly higher among high-risk patients (92.3%) compared with low-risk individuals (58.1%; p<0.001). When evaluated as a continuous variable, the BAN-ADHF score was significantly associated with mortality (OR≈1.10 per unit, p<0.001). Using the predefined threshold of ≥12, high-risk patients had an approximately 3.8-fold higher risk of death (95% CI 1.8–8.0, p=0.001). In multivariable logistic regression adjusted for age, admission NYHA class, log(NT-proBNP), GFR, hemoglobin level and log(CRP), BAN-ADHF remained independent predictor of long-term mortality (95% CI 1.02-1.44, p=0.0251). Conclusion The BAN-ADHF score identified patients with acute HFpEF at risk of long-term mortality. Individuals classified as high-risk (BAN-ADHF ≥ 12) experienced a nearly fourfold increase in five-year mortality compared with those in the low-risk group. In multivariable analysis BAN-ADHF retained its independent prognostic significance. These results highlight the score’s value as a tool for early risk stratification in acute HFpEF.
No takes yet. Share an insight, caveat, or question.
Blagojevic et al. (2026) conducted a cohort in Acute heart failure with preserved ejection fraction (HFpEF) (n=143). BAN-ADHF score ≥12 (high-risk) vs. BAN-ADHF score <12 (low-risk) was evaluated on 5-year all-cause mortality (OR 3.8, 95% CI 1.8-8.0, p=0.001). A high BAN-ADHF score (≥12) was associated with a significantly higher 5-year all-cause mortality compared to a low score (92.3% vs 58.1%; OR 3.8, 95% CI 1.8-8.0, p=0.001) in acute HFpEF patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: